Skip to main content

NeuroSense Therapeutics Ltd.

NRSN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001875091

No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.

Other share classesNRSNW

13F holders, Q4 2024

Institutional positions in NeuroSense Therapeutics Ltd. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
13
+6 vs. Q3 2024
Shares held
646.5K
+421.2K (+186.9%) vs. Q3 2024
Total value
$775.8K
+$489.9K (+171.4%) vs. Q3 2024
New holders
7
3 more added
Sold out
1
1 more reduced

Compare with Q3 2024: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting NRSN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2024: 13 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 0 institutionsQ4 2021: 5 institutionsQ1 2022: 9 institutionsQ2 2022: 7 institutionsQ3 2022: 5 institutionsQ4 2022: 5 institutionsQ1 2023: 5 institutionsQ2 2023: 6 institutionsQ3 2023: 5 institutionsQ4 2023: 8 institutionsQ1 2024: 8 institutionsQ2 2024: 7 institutionsQ3 2024: 7 institutionsQ4 2024: 13 institutionsQ1 2025: 11 institutionsQ2 2025: 17 institutionsQ3 2025: 10 institutionsQ4 2025: 13 institutionsQ1 2026: 13 institutionsQ2 2026: 12 institutions
Value heldQ4 2024: $775.8K
Q1 2021: $0Q2 2021: $0Q3 2021: $0Q4 2021: $380.0KQ1 2022: $694.0KQ2 2022: $733.0KQ3 2022: $132.0KQ4 2022: $41.6KQ1 2023: $243.4KQ2 2023: $2.34MQ3 2023: $554.1KQ4 2023: $110.6KQ1 2024: $303.9KQ2 2024: $1.87MQ3 2024: $285.9KQ4 2024: $775.8KQ1 2025: $180.8KQ2 2025: $964.4KQ3 2025: $346.8KQ4 2025: $266.2KQ1 2026: $286.7KQ2 2026: $285.7K
Institutions holding NRSN and their total value by quarter
QuarterHoldersValue
Q2 202612$285.7K
Q1 202613$286.7K
Q4 202513$266.2K
Q3 202510$346.8K
Q2 202517$964.4K
Q1 202511$180.8K
Q4 202413$775.8K
Q3 20247$285.9K
Q2 20247$1.87M
Q1 20248$303.9K
Q4 20238$110.6K
Q3 20235$554.1K
Q2 20236$2.34M
Q1 20235$243.4K
Q4 20225$41.6K
Q3 20225$132.0K
Q2 20227$733.0K
Q1 20229$694.0K
Q4 20215$380.0K
Q3 20210$0
Q2 20210$0
Q1 20210$0

Institutions, Q4 2024

Shares, value and share of portfolio for each institution holding NeuroSense Therapeutics Ltd.; share changes are against Q3 2024.

Institutions holding NRSN in Q4 2024
InstitutionSharesValue% of portfolioChange in sharesAction
Citadel Advisors LLC253,997$304.8K0.00%+219,717+640.9%Added
Morgan Stanley102,581$123.1K0.00%+102,581New
Jane Street Group, LLC64,636$77.6K0.00%+64,636New
HRT Financial LP64,390$77.0K0.00%+64,390New
XTX Topco Ltd41,897$50.3K0.00%−4,099−8.9%Reduced
Meitav Dash Investments Ltd40,000$48.0K0.00%00.0%Unchanged
Stratos Wealth Partners, LTD.20,000$24.0K0.00%+20,000New
Commonwealth Equity Services, LLC16,250$20.0K0.00%+3,625+28.7%Added
Geode Capital Management, LLC15,870$19.0K0.00%+3,907+32.7%Added
Two Sigma Securities, LLC15,017$18.0K0.00%+15,017New
Warberg Asset Management LLC10,700$12.8K0.00%+10,700New
CWM, LLC1,000$1.00K0.00%00.0%Unchanged
SBI Securities Co., Ltd.175$2100.00%+175New
Cantor Fitzgerald, L. P.0$00.00%−79,492−100.0%Sold out